Peptide directory

Find a peptide

Public profiles inside a larger governed registry

Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.

Browse the Master Registry Explore research atlases Find studies worldwide

The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.

Published profiles

Search profiles and sources

Compare peptides side by side →

Refine by category

Category

405 peptide records

PTHrP analog
Abaloparatide
Peptide analog
Emerging
Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.
Evidence and record details
Evidence integrity map
Human 1Preclinical 0Durable IDs 6Open signals 2
Publication state
Published profile
Verified source records
25 source records verified
Chemistry record
Chemistry record on file
Regulatory entries
2 published regulatory entries
Research questions
4 open research questions
Evidence review date
Documented human review recorded Sep 20, 2026
Source verification checks records; it does not itself approve scientific conclusions.
View evidence profile for Abaloparatide
Amylin receptor research peptide
AC187
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for AC187 →
Synthetic cosmetic peptide
Acetyl hexapeptide-8
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Acetyl hexapeptide-8 →
ACTH peptide fragment
ACTH(1-17)
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for ACTH(1-17) →
ACTH peptide fragment
ACTH(4-10)
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for ACTH(4-10) →
Endogenous growth factor protein
Activin A
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Activin A →
Endogenous peptide hormone
Adrenocorticotropic hormone
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Adrenocorticotropic hormone →
Endogenous vasoactive peptide
Adrenomedullin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Adrenomedullin →
Endogenous vasoactive peptide
Adrenomedullin 2
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Adrenomedullin 2 →
Endogenous peptide
Adropin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Adropin →
Melanocortin peptide analog
Afamelanotide
Peptide analog
Emerging
Afamelanotide is a melanocortin peptide analog. The research record considers pigmentation biology and clinical outcomes in erythropoietic protoporphyria, alongside distinct exploratory questions such as UV responses and vitiligo. These settings should be kept separate.
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 5Open signals 2
Publication state
Published profile
Verified source records
45 source records verified
Chemistry record
Chemistry record on file
Regulatory entries
2 published regulatory entries
Research questions
No open questions documented
Evidence review date
No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
View evidence profile for Afamelanotide
Spider-venom peptide
Agatoxin IVA
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Agatoxin IVA →
Endogenous neuropeptide
Agouti-related peptide
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Agouti-related peptide →
Endogenous vasoactive peptide
Alamandine
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Alamandine →
GLP-1 analog fusion protein
Albiglutide
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Albiglutide →
Growth hormone secretagogue peptide
Alexamorelin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Alexamorelin →
Endogenous neuropeptide
Alpha-CGRP
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Alpha-CGRP →
Research reference
Alpha-conotoxin GI
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Alpha-conotoxin GI →

How the public directory relates to the 500-record Master Registry

master registry transparency

500 master records, with governance status shown explicitly

WPF-MASTER-REGISTRY-TRANSPARENCY-1.0

501

Master records

467

Governed records

Review-deferred

458

Peptide acquisition eligible

Governed comparators

The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.

Explore the full Master Registry →

What the profile status labels mean

Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.

Find a peptide

Search profiles and sources

500 master records, with governance status shown explicitly

Recently updated public records